During the ESC Congress 2016, held in Rome, Italy, PACE-CME organised a satellite symposium, in which the role of PCSK9 proteins in cardiovascular disease was discussed, as well as the emerging development of clinically potent PCSK9 inhibitors.
Prof John Kastelein focussed his lecture on genetic dyslipidaemia, such as familiar hypercholesterolaemia(FH). FH is very prevalent in Western society and is estimated to occur in 1 in 200 people.
As of the discovery of statins in the prevention of CHD in 1994, treatment of cardiovascular (CV) disease and LDL-c reduction rapidly advanced. Today we have many potential new medications beyond statins and the question now is, should we use them, in whom and to what purpose.
According to Gilles Lambert the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) as a therapeutic target started with the LDL receptor (LDL-R). The LDL-R situates on the surface of most cell types, but most importantly on liver cells